The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study

Carter, H.; Zannino, D.; John Simes, R.; Schofield, D.; Howard, K.; Zalcberg, J.; Price, T.; Tebbutt, N.

doi:10.1016/j.ejca.2013.09.028

The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study

Date

2014

Authors

Carter, H.

Zannino, D.

John Simes, R.

Schofield, D.

Howard, K.

Zalcberg, J.

Price, T.

Tebbutt, N.

Type:

Journal article

Citation

European Journal of Cancer, 2014; 50(3):535-543

Statement of Responsibility

Hannah E. Carter, Diana Zannino, R. John Simes, Deborah J. Schofield, Kirsten Howard, John R. Zalcberg, Timothy J. Price, Niall C. Tebbutt

DOI

10.1016/j.ejca.2013.09.028

Abstract

Abstract not available

Description

Link to a related website: https://ses.library.usyd.edu.au/bitstream/2123/14140/2/MAX%20health%20economics%2029Jan13.pdf, Open Access via Unpaywall

Rights

Published Version

https://doi.org/10.1016/j.ejca.2013.09.028

Persistent link to this record

http://hdl.handle.net/2440/91149

Full item page

The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study

Date

Authors

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Citation

Statement of Responsibility

Conference Name

DOI

Abstract

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

License

Grant ID

Published Version

Call number

Persistent link to this record